Oppenheimer assumed coverage on shares of MBX Biosciences (NYSE:MBX - Free Report) in a research note released on Wednesday, Marketbeat.com reports. The firm issued an outperform rating and a $38.00 target price on the stock.
Other equities analysts have also recently issued research reports about the company. Guggenheim restated a "buy" rating and issued a $44.00 price target on shares of MBX Biosciences in a research report on Thursday, April 10th. JMP Securities began coverage on MBX Biosciences in a research report on Thursday, April 10th. They issued a "market outperform" rating and a $38.00 price target on the stock. Finally, Citizens Jmp began coverage on MBX Biosciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $38.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $37.57.
Check Out Our Latest Report on MBX Biosciences
MBX Biosciences Stock Performance
MBX stock traded down $0.44 during trading on Wednesday, hitting $11.75. The company had a trading volume of 273,419 shares, compared to its average volume of 264,355. MBX Biosciences has a 1-year low of $4.81 and a 1-year high of $27.50. The firm has a 50-day moving average price of $11.80 and a 200-day moving average price of $10.61.
Hedge Funds Weigh In On MBX Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of MBX Biosciences in the 4th quarter worth approximately $1,720,000. Nuveen Asset Management LLC acquired a new stake in shares of MBX Biosciences in the 4th quarter worth approximately $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of MBX Biosciences in the 4th quarter worth approximately $117,000. Citadel Advisors LLC grew its holdings in shares of MBX Biosciences by 62.5% in the 4th quarter. Citadel Advisors LLC now owns 220,330 shares of the company's stock worth $4,061,000 after acquiring an additional 84,722 shares during the period. Finally, Deutsche Bank AG acquired a new stake in MBX Biosciences during the 4th quarter valued at $80,000.
About MBX Biosciences
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Featured Articles
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
